Mesoblast Ltd traded at 0.65 this Tuesday June 28th, decreasing 0.02 or 2.99 percent since the previous trading session. Looking back, over the last four weeks, Mesoblast Ltd lost 34.34 percent. Over the last 12 months, its price fell by 68.29 percent. Looking ahead, we forecast Mesoblast Ltd to be priced at 0.68 by the end of this quarter and at 0.63 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Avita Therapeutics Inc 1.58 -0.04 -2.48% -70.51%
Cochlear 202.28 -0.61 -0.30% -19.49%
CSL 274.03 1.03 0.38% -5.46%
Clinuvel Pharmaceuticals Ltd 15.93 -0.20 -1.24% -45.67%
Opthea Ltd 1.18 0.06 4.89% -9.23%
Paradigm Biopharmaceuticals Ltd 0.93 -0.06 -6.09% -52.32%
Pacific Edge 0.69 -0.03 -4.17% -43.90%
PYC Therapeutics Ltd 0.07 0.01 8.96% -51.33%
Ramsay Health Care 73.55 -0.09 -0.12% 16.67%
Sonic Healthcare 33.15 0.08 0.24% -12.49%
Starpharma Holdings Ltd 0.67 0.01 0.76% -55.07%
Telix Pharmaceuticals Ltd 4.75 -0.03 -0.63% -18.80%

Indexes Price Day Year
AUALL 6953 59.80 0.87% -8.09%
AU200 6764 57.60 0.86% -7.36%

Mesoblast Ltd
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.